Drug Search Results
More Filters [+]

TAK-285

Alternative Names: tak-285, tak285, tak 285
Latest Update: 2024-04-01
Latest Update Note: PubMed Publication

Product Description

TAK-285 is a novel low-molecular weight compound that was designed, synthesized by Takeda Pharmaceutical Company, Osaka, Japan, and has been shown to selectively and potently inhibit HER2 and EGFR kinase activities.Ê (Sourced from: https://drugs.ncats.io/drug/70CCB438L6)

Mechanisms of Action: EGFR Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for TAK-285

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Oncology Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

TAK-285_101

P1

Completed

Oncology Unspecified

2011-06-01

Recent News Events